Synthetic Biologics Stock Price

0.00 (0.0%)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Synthetic Biologics Inc SYN AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.4483 04:00:01
Open Price Low Price High Price Close Price Prev Close
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.4483 USD


Draw Mode:

Synthetic Biologics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 59.19M 132.04M 131.94M $ - $ - -0.66 -1.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 4.30%

more financials information »

Synthetic Biologics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SYN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.5010.51970.4430.47695831,485,062-0.0527-10.52%
1 Month0.4510.55750.4430.49417511,830,218-0.0027-0.6%
3 Months0.62850.63970.42990.51418351,768,580-0.1802-28.67%
6 Months0.79750.79940.42990.57324692,641,123-0.3492-43.79%
1 Year0.501.700.2610.80860286,993,612-0.0517-10.34%
3 Years2.358.000.250.83242262,597,406-1.90-80.92%
5 Years59.5066.500.255.011,941,235-59.05-99.25%

Synthetic Biologics Description

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria.

Your Recent History
Synthetic ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.